Innovative MulticOmponent Drug dEsign (IMODE) for enhancing regional strategic advantages in pharmaceutical and biomedical applications | 2 Mers Seas Zeeën

IMODE

You are here

Innovative MulticOmponent Drug dEsign (IMODE) for enhancing regional strategic advantages in pharmaceutical and biomedical applications

Priority Axis

Technological and Social Innovation

Specific objective

Technological Innovation

Lead partner

University Lille 1 - Unité Matériaux et Transformations

Contact

Start Date

01/07/2016

End Date

30/06/2021

Project budget

5 960 060

ERDF amount

3 576 036

ERDF rate

60%

    About

    Common challenge

    The IMODE project is motivated by an unmet need for developing solutions to address societal challenges for improved healthcare, novel medicines while maintaining low medical costs. This will be achieved with the collaboration of academic research groups and SMEs through a transdisciplinary applied research programme in materials science, pharmacy, biology and medicine. The project will strengthen innovation in the 2 Seas Area in order to obtain a strategic advantage for novel pharmaceutical and medical applications bridging the current gap between academia and the private sector.

    Main Achievements

    The objective of IMODE is to enhance R&D on major societal challenges for improved healthcare by developing solutions for novel pharmaceutical products and medical devices through new multicomponent drug systems. It is based on the international joint collaboration between academic research groups, SMEs, one large company and one economic development agency.

    After 42 months of implementation, many achievements have been obtained: 

    • Development of a new technique that allows: i) significant time saving for multicomponent formulation screening and ii) reducing costs since it requires very low quantities of drug. The developed technology is ready-to-use and has been developed in collaboration with two SMEs involved in the partnerships with the aim to be implemented as a part of their future advanced products/services to increase theur competitiveness.
    • Design of 3 novel pharmaceutical cocrystal compounds with improved stability and dissolution rates using Hot Melt Extrusion processing. 3 Patents have been filed. The new products will be potentially marketed by one partner (Cubic Pharmaceutical limited) or licenced to other pharmaceutical companies and hence enhance the company’s annual turnover.
    • Development of Non-viral hybrid polysaccharide nanogel for gene delivery. The nanogel is composed of well recognized materials and the manufacturing method is scalable and industrially feasible. 
    • Development of an ingenious protocol to improve the dissolution rate of poorly water soluble drugs in the polymer matrix of an amorphous solid dispersion, ensuring a greater efficacy of the drug upon administration to the patient.
    • Identification of a new robust bio-based excipient for sustained release matrix tablets. 
    • Development of a new thin polymeric films for “colon targeting” drugs.
    • Optimization of the proprietary 3D printing technology for stent fabrication and the development of a new novel stent design with excellent mechanical properties and performance. 
    • Development of novel printing bioresorbable filaments comprising of single polymers or polymer composites for stent printing
    • Organisation of three IMODE conventions in the framework of BIOFIT (2018, LILLE), MEDFIT (2019, Lille) and BIOFIT (2019, Marseille) focusing on Innovative pharmaceutical formulations and technologies and medical devices. The first Press conference took place during the MedFIT event (2019, Lille).

    Partnership

    Partners

    University College London, UCL School of Pharmacy

    Université Lille 2 Droit et Santé

    Universiteit Gent Laboratory of Pharmaceutical Technology

    University of East Anglia

    ImaBiotech

    University of Greenwich

    G.I.E Eurasanté

    Ashford and St Peter's Hospital's NHS Foundation Trust

    Cubic Pharmaceuticals Limited

    Roquette Frères

    Outputs

    Theme
    Type
    Target
    URL / Download
    30/09/2019

    Prototypes of the technique for offline preformulation screening and inline process optimisation analysis (TRL5)

    Theme: Health care - Innovation
    Type: Method/tool
    Target: Citizens - Schools and training centres - SMEs /enterprises
    30/09/2019

    Design of new drug-drug compound combinations (TRL5). 

    Theme: Health care - Innovation
    Type: Method/tool
    Target: Citizens - Schools and training centres - SMEs /enterprises
    30/09/2019

    Development of innovative tech. for materials formulation (TRL4)

    Theme: Health care - Innovation
    Type: Method/tool
    Target: Citizens - Schools and training centres - SMEs /enterprises
    30/09/2019

    Stability- enhanced hot-melt extruded co-amorphous solid dispersion (TRL4). 

    Theme: Health care - Innovation
    Type: Method/tool
    Target: Citizens - Schools and training centres - SMEs /enterprises
    31/12/2019

    Bio-based matrix solid dosage form for oral controlled drug delivery (TRL5). 

    Theme: Health care - Innovation
    Type: Method/tool
    Target: Citizens - Schools and training centres - SMEs /enterprises
    30/09/2019

    Advanced drug delivery systems for colon targeting (TRL4)

    Theme: Health care - Innovation
    Type: Method/tool
    Target: Citizens - Schools and training centres - SMEs /enterprises